| Serial Number | 97187198 |
| Word Mark | SWANBIO THERAPEUTICS |
| Filing Date | Thursday, December 23, 2021 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, September 30, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, January 2, 2024 |
| Goods and Services | Therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapy, namely, gene inhibition therapy and RNA interference (RNAi), for the treatment of genetic diseases and disorders and neurological diseases and disorders; therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapy, namely, gene augmentation therapy, for the treatment of genetic diseases and disorders and neurological diseases and disorders; therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapies using intrathecal administration, for the treatment of genetic diseases and disorders and neurological diseases and disorders; biologic preparations for use in the treatment of genetically based diseases and disorders; biologic preparations for medical purposes, namely, for gene therapy for treating genetic disorders; pharmaceutical preparations that modulate RNA expression for the treatment of neurological diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; gene therapy products, namely, gene delivery pharmaceuticals for the treatment of genetic diseases and disorders and neurological diseases and disorders; pharmaceutical preparations for gene therapy, gene inhibition and gene augmentation, for the treatment of genetic diseases and disorders and neurological diseases and disorders; viruses, viral vectors and viral constructs, all in the nature of pharmaceutical preparations, for the treatment of neurological diseases and disorders and genetic diseases and disorders; pharmaceutical preparations for gene therapy, for the treatment of genetic diseases and disorders and neurological diseases and disorders; pharmaceutical and biopharmaceutical agents for the treatment of genetic disorders and neurological diseases and disorders; pharmaceutical preparations, namely, nucleic acid therapeutics for the treatment of genetic disorders and neurological diseases and disorders; pharmaceutical preparations, namely, DNA and RNA therapeutics for the treatment of genetic disorders and neurological diseases and disorders; none of the foregoing constituting reagents or probes or for the purpose of detecting and analyzing molecules in protein or nucleotide arrays |
| Pseudo Mark | SWAN BIO THERAPEUTICS |
| Goods and Services | Development of pharmaceutical preparations for use in gene therapy; genetic engineering and biotechnology research; research and development of new products in the field of gene therapeutics; scientific and medical research in the field of genetics, gene therapy and genetic engineering; laboratory research in the fields of genetics, gene therapy, drug development, biotechnology, microbiology and molecular biology; pharmaceutical drug discovery; scientific research in the field of gene therapy discovery; drug development and therapeutic drug development; genetic drug development and therapeutic drug development; biological research; biological drug development and scientific research in the field of biological development; none of the foregoing relating to reagents or probes or for the purpose of detecting and analyzing molecules in protein or nucleotide arrays |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, December 30, 2021 |
| Primary Code | 005 |
| First Use Anywhere Date | Thursday, December 7, 2017 |
| First Use In Commerce Date | Tuesday, May 15, 2018 |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, April 11, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | SwanBio Therapeutics Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | Bala Cynwyd, PA 19004 |
| Party Name | SwanBio Therapeutics Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Bala Cynwyd, PA 19004 |
| Event Date | Event Description |
| Thursday, December 30, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, September 27, 2022 | ASSIGNED TO EXAMINER |
| Tuesday, October 11, 2022 | NON-FINAL ACTION WRITTEN |
| Tuesday, October 11, 2022 | NON-FINAL ACTION E-MAILED |
| Tuesday, October 11, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, April 10, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, April 10, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, April 11, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, June 8, 2023 | NON-FINAL ACTION WRITTEN |
| Thursday, June 8, 2023 | NON-FINAL ACTION E-MAILED |
| Thursday, June 8, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, September 8, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, September 8, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, September 8, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, November 28, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, December 13, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, January 2, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, February 27, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Monday, September 30, 2024 | ABANDONMENT - NO USE STATEMENT FILED |
| Monday, September 30, 2024 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Tuesday, January 2, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |